ArticleBMC infectious diseases2022
Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia.
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of Carbapenem-Resistant Enterobacteriaceae in Intensive Care Units in Saudi Arabia:Saudi medical journal · 2026Pooled it
- Systematic review of multidrug-resistantFrontiers in microbiology · 2025Pooled it
- Prevalence and molecular typing of carbapenem-resistant Enterobacterales in a secondary-care hospital in Jazan region, Saudi Arabia.New microbes and new infections · 2026Article
- Epidemiology, Molecular Characteristics, Treatment Patterns, and Outcomes of Carbapenem-Resistant Enterobacterales Infections in a Tertiary Hospital in Southern Saudi Arabia: A Retrospective Cohort Study.Journal of epidemiology and global health · 2026Article
- Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.BMC infectious diseases · 2026Article
- Detection of New Delhi metallo-β-lactamase (blaScientific reports · 2026Article
- Epidemiology and carbapenemase gene distribution among carbapenem-resistant enterobacterales: a two-year retrospective study in a Saudi tertiary hospital.BMC microbiology · 2026Article
- Resistance to novel antimicrobial agents among NDM-and OXA-48-producing Carbapenem-resistant Enterobacterales in Lebanon.Frontiers in cellular and infection microbiology · 2026Article
- Clinical outcomes and treatment effectiveness in patients with carbapenem-resistant Enterobacterales infections: a multicenter retrospective cohort study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Molecular characterization ofPeerJ · 2026Article
- Recurrence, Readmission, and Key Mortality Predictors in Patients with Carbapenem-Resistant Enterobacterales Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Urinary Tract Infections Caused by Extended-Spectrum Beta-Lactamase-Producing and Carbapenem-Resistant Enterobacterales in Saudi Arabia: Impact of Catheterization.Medicina (Kaunas, Lithuania) · 2025Article
- Molecular Analysis of Tigecycline Resistance in Carbapenem-Resistant Enterobacterales (CRE) in Mthatha and Surrounding Hospitals.Antibiotics (Basel, Switzerland) · 2025Article
- Epidemiology and outcomes of Carbapenem-resistant Enterobacterales infection in high-risk patients in Saudi Arabia.Frontiers in microbiology · 2025Article
- Bacteremia in the Gulf Cooperation Council Region: A Review of the Literature 2013-2023.Infection and drug resistance · 2025Review
- High prevalence of antimicrobial resistance genes in multidrug-resistant-ESBLs-producingIranian journal of microbiology · 2024Article
- Clinical and epidemiological characteristics of multi-drug resistantJournal of medicine and life · 2024Article
- Treatment of a challenging NDM and OXA-48-producingIDCases · 2024Article
- Molecular Screening of Carbapenem-ResistantJournal of clinical medicine · 2023Article
- Klebsiella pneumoniae bacteraemia epidemiology: resistance profiles and clinical outcome of King Fahad Medical City isolates, Riyadh, Saudi Arabia.BMC infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe burden of carbapenem resistance is not well studied in the Middle East. We aimed to describe the molecular epidemiology and outcome of carbapenem-resistant Enterobacterales (CRE) infections from several Saudi Arabian Centers.
methodsThis is a multicenter prospective cohort study conducted over a 28-month period. Patients older than 14 years of age with a positive CRE Escherichia coli or Klebsiella pneumoniae culture and a clinically established infection were included in this study. Univariate and multivariable logistic models were constructed to assess the relationship between the outcome of 30-day all-cause mortality and possible continuous and categorical predictor variables.
resultsA total of 189 patients were included. The median patient age was 62.8 years and 54.0% were male. The most common CRE infections were nosocomial pneumonia (23.8%) and complicated urinary tract infection (23.8%) and 77 patients (40.7%) had CRE bacteremia. OXA-48 was the most prevalent gene (69.3%). While 100 patients (52.9%) had a clinical cure, 57 patients (30.2%) had died within 30 days and 23 patients (12.2%) relapsed. Univariate analysis to predict 30-day mortality revealed that the following variables are associated with mortality: older age, high Charlson comorbidity index, increased Pitt bacteremia score, nosocomial pneumonia, CRE bacteremia and diabetes mellitus. In multivariable analysis, CRE bacteremia remained as an independent predictor of 30 day all-cause mortality [AOR and 95% CI = 2.81(1.26-6.24), p = 0.01].
conclusionsThese data highlight the molecular epidemiology and outcomes of CRE infection in Saudi Arabia and will inform future studies to address preventive and management interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.